Interview with Dr. Ahmed Sheriff on CRP apheresis for COVID-19 patients
08.06.2021
ntv has broadcast an interview with Dr. Ahmed Sheriff about CRP apheresis for COVID-19 patients. Among other things, they talk about the lack of funding for medical devices in the Corona Pandemic.
Sat.1 reports on CRP apheresis as salvation for COVID-19 patients
19.05.2021
The Sat.1 morning show has reported on CRP apheresis treatment for COVID-19 patients.
At the Klinikum Havelhöhe, the therapy is now used for many severely ill Corona patients - with promising results. Nevertheless, all funding applications for a large clinical trial were unsuccessfully rejected. The trial is needed to make the therapy available to COVID-19 patients throughout Germany.
ZDF reports on CRP apheresis as salvation for COVID-19 patients
18.05.2021
ZDF has reported on CRP apheresis treatment for COVID-19 patients.
At the Klinikum Havelhöhe, the therapy is now used for many severely ill Corona patients - with promising results. Nevertheless, all funding applications for a large clinical trial were unsuccessfully rejected. The trial is needed to make the therapy available to COVID-19 patients throughout Germany.
Forum Sanitas reports about the dark side of CRP
07.05.2021
In the 2nd issue 2021 of Forum Sanitas an article about the dark side of CRP has been published.
The latest findings on the pathological action of CRP are summarized and the potential clinical applications of CRP apheresis in acute myocardial infarction, COVID-19, and other conditions are described.
Promising treatment success in patients with severe COVID-19 courses
Hennigsdorf, 21.04.2021 – Pentracor GmbH, a medical technology company based in Hennigsdorf near Berlin (convertible bond ISIN: DE000A289XB9, WKN: A289XB), active in the dynamically growing healthcare sector, has achieved further promising treatment successes with its CE-certified and patent-protected medical product PentraSorb® CRP in patients with severe COVID-19 courses. For example, the Havelhöhe Community Hospital in Berlin has been using Pentracor's new therapeutic extracorporeal treatment method for severely ill COVID-19 patients for several weeks and has already achieved a significant improvement in the patients' clinical condition after a short period of time.
Published Papers
Article about the CAMI-1 study published in "Intensiv-News"
12.07.2021
In the 3rd issue of "Intensiv-News" 2021, the most recent publications on CRP apheresis were summarized and evaluated with a focus on the recently published CAMI-1 study.
Clinical trial CRP apheresis after myocardial infarction published
11.03.2021
Results of the first clinical trial of CRP apheresis after acute myocardial infarction (CAMI1) were published in the cardiology journal Frontiers in Cardiovascular Medicine.
"CRP apheresis as anti-inflammatory therapy for acute myocardial infarction: results from the CAMI-1 trial."
The article describes that C-reactive protein substantially triggers myocardial damage after myocardial infarction.
Review on the pathomechanism of CRP published
10.02.2021
"C-reactive protein triggers cell death in ischemic cells":
In the Research Topic "Diagnostic and Therapeutic Applications of Pentraxin and Pentraxin-Associated Proteins" of the journal Frontiers in Immunology, a review on the pathomechanism of CRP in organ-damaging inflammation was published.
Review on CRP apheresis published
12.09.2020
In this article, the current scientific knowledge of the pathological function of CRP is concisely summarized and the therapeutic concept of CRP apheresis is explained in detail on the basis of the clinical CAMI-1 study (after myocardial infarction) and CASTRO-1 study (after stroke).
Direct effect of CRP on blood pressure and gene regulation published
30.08.2020
In the scientific journal Frontiers in Immunology an article was published in which the effect of human CRP on blood pressure and heart rate of rabbits was investigated.
Webinars
Teaser for the webinar "Anti-inflammatory strategies for COVID-19"
Dezember 2020
Here is a “short” teaser to record our webinar on anti-inflammatory strategies for COVID-19, which is intended to provide an overview of what we believe to be the most exciting topics, key messages and areas of conflict at the event.
1st Webinar about CRP apheresis in COVID-19
14.12.2020
Pentracor GmbH recently held its first webinar with renowned physicians from Germany and Switzerland to discuss the increasingly clear relevance of the pathological function of CRP in the inflammatory, severe phase of COVID-19.
Events
"Neutron" podcast presents CRP apheresis
21.05.2021
On the Neutron podcast, CRP apheresis was introduced and explained, and Dr. Ahmed Sheriff was interviewed. The focus was on the use of the therapy in COVID-19 patients.
bbb Lunch & Learn "COVID-19 patients successfully treated with CRP blood wash - a new therapy option in the pandemic."
19.05.2021
As part of the Lunch & Learn event series of the Biotechnologieverbund Berlin-Brandenburg (bbb), Dr. Ahmed Sheriff presented the PentraSorb® CRP and reported on its use at Klinikum Havelhöhe, where almost all COVID-19 patients are now treated with CRP apheresis. Afterwards there was an exciting discussion.
Industry Symposium at the DGK
07.04.2021
An Industry Symposium about CRP, Lp(a) and Hydration is organized by Pentracor together with Kaneka at the 87th Annual Meeting of the DGK.
Care Sympsoium at the ISFA/E-ISFA about CRP apheresis
20.03.2021
Pentracor organizes a Care Symposium about CRP apheresis at the 13th ISFA & E-ISFA Congress.
Awards
Pentracor nominated for the "Zukunftspreis Brandenburg" 2021
Twelve companies have been nominated by the main jury for the "Zukunftspreis Brandenburg" 2021. Six prize winners and one company as a special prize winner will be awarded Brandenburg's most important business prize in the final on November 12 at the Airport Center Berlin Schönefeld. Pentracor GmbH, based in Hennigsdorf, is among the nominees. "We are very honored by the nomination," said Pentracor CEO Dr. Ahmed Sheriff.
2nd place for Prof. Torzewski at the GMA
18.11.2020
He was awarded in the category 'Medical Innovation Practices & Clinics - Cardiology' for the application of the innovative CRP apheresis after myocardial infarction. He prevailed against almost all colleagues, in particular also from university hospitals and heart centers.
Project "C-reactive protein and cardiovascular diseases" was nominated for the German Medical Award
01.10.2020
We are pleased to announce that Prof. Dr. Jan Torzewski of the Klinikum Kempten and Klinik Immenstadt from the Klinikverbund Allgäu has been nominated for the German Medical Award.
CAMI1 study was Highlight at the 85th DGK Annual Meeting
27.04.2019
Das Poster “Selective CRP apheresis as a new treatment option in STEMI: Final results of the CAMI1 Study” von der CAMI1-Studiengruppe wurde als Highlight der DGK Jahrestagung im Bereich “Interventionelle Kardiologie” vorgestellt.
Abstract prize at the DGfN Annual Meeting 2018
25.07.2018
The abstract "Selective CRP apheresis as a new therapeutic option in the treatment of acute myocardial infarction (STEMI)" by Dr. Wolfgang Ries was awarded as one of the 10 best at the 10th Annual Meeting of the German Society for Nephrology (DGfN) 2018.
Poster prize at 84th Annual Meeting of DGK
07.04.2018
The poster "Selective CRP apheresis as a new treatment option in acute myocardial infarction (CAMI1 study)" by Prof. Dr. Christoph Garlichs was awarded a poster prize at the 84th Annual Meeting of the DGK.
Other
Pentracor donates Corona rapid tests to the Berliner Stadtmission
03.12.2020
To meet the strict hygiene requirements for emergency overnight stays, the Berliner Stadtmission has an increasing need for Corona rapid tests for guests and staff.
The 100th patient was successfully treated with CRP apheresis
14.10.2020
Der 100. Patient wurde dieser Tage mit der CRP-Apherese behandelt. Diese Behandlung lief im Rahmen der CABY1-Studie (CRP-Apherese nach koronarer Bypass-Operation) und wurde wie gewohnt sicher durchgeführt. Wir freuen uns, dass nun schon 100 Patienten von der Therapie profitieren konnten und hoffen, noch zahlreichen weiteren Menschen helfen zu können.
Pentracor GmbH celebrates its 10th anniversary!
25.08.2010
On August 25, 2010, Dr. Ahmed Sheriff together with Birgit Vogt, Dr. Rudolf Kunze, Stephan Hiller and Dr. Bernd Wegener founded Pentracor GmbH to implement the idea of CRP apheresis for acute inflammation-driven diseases such as myocardial infarction.
